Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 3/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | ACP1 | P24666 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | LATS1 | O95835 | 1/20 | 0.55 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453642 | 0.87 | ALDH1A1 (0.71) | PDE5APTGS1TBXAS1PTGS2MAPK1 | |
| SCHEMBL3460213 | 0.86 | ACP1 (0.71) | PDE5APTGS1TBXAS1PTGS2ACP1 | |
| SCHEMBL17799806 | 0.83 | SLC6A3 (0.77) | PDE5APTGS1TBXAS1PTGS2ACP1 | |
| SCHEMBL3459468 | 0.82 | MAPK1 (0.82) | PDE5APTGS1TBXAS1PTGS2ACP1 | |
| SCHEMBL11836022 | 0.81 | ACP1 (0.51) | PDE5AACP1MAPK1MEN1KMT2A | |
| SCHEMBL16964812 | 0.80 | LATS1 (0.65) | PDE5APTGS1TBXAS1PTGS2KDM4E | |
| SCHEMBL15644754 | 0.80 | LATS1 (0.65) | PDE5APTGS1TBXAS1PTGS2KDM4E | |
| SCHEMBL3459768 | 0.80 | PDE5A (0.76) | PDE5APTGS1TBXAS1PTGS2ACP1 | |
| SCHEMBL3460199 | 0.79 | ACP1 (0.60) | PDE5APTGS1TBXAS1PTGS2ACP1 | |
| SCHEMBL7277479 | 0.78 | PDE5A (1.00) | PDE5APTGS1TBXAS1PTGS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161651-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2007-07-12 | — | — | US | claimed |
| US-7763627-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763627-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763627-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| EP-1610774-A4 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070161651-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1610774-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004092196-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161651-A1 | Tie-2 modulators and methods of use | TIE1, TEK, KDR | PDE5A 1963/4885PTGS1 435/4885TBXAS1 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.